Alfred Garfall

List of Publications by Year
in descending order

76 papers	5,989 citations	186265 28 h-index	85541 71 g-index
77 all docs	77 docs citations	77 times ranked	8692 citing authors

#	Article	IF	Citations
1	NY-ESO-1â€"specific TCRâ€"engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 2015, 21, 914-921.	30.7	728
2	IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes and Development, 2010, 24, 241-255.	5.9	594
3	B cell maturation antigenâ€"specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	8.2	513
4	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1040-1047.	27.0	511
5	Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes and Development, 2011, 25, 2465-2479.	5.9	454
6	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	30.7	365
7	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell, 2016, 30, 120-135.	16.8	311
8	Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2022, 387, 495-505.	27.0	291
9	Carfilzomib-Associated Cardiovascular Adverse Events. JAMA Oncology, 2018, 4, e174519.	7.1	196
10	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematology,the, 2015, 2, e408-e416.	4.6	158
11	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	5.0	140
12	Teclistamab, a B-cell maturation antigenâ€Ã—â€CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet, The, 2021, 398, 665-674.	13.7	138
13	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	4.9	138
14	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 2019, 3, 2812-2815.	5.2	133
15	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1946-1955.	1.6	128
16	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1154-1165.	4.9	113
17	Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer. Cancer Research, 2007, 67, 7378-7385.	0.9	108
18	NCCN GuidelinesÂ® Insights: Multiple Myeloma, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 8-19.	4.9	80

#	ARTICLE	IF	CITATIONS
19	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Letters, 2016, 371, 117-124.	7.2	59
20	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. Blood, 2016, 128, 1147-1147.	1.4	56
21	Promoting Professionalism through an Online Professional Development Portfolio: Successes, Joys, and Frustrations. Academic Medicine, 2007, 82, 1065-1072.	1.6	52
22	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 27-27.	1.4	51
23	Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes and Development, 2016, 30, 220-232.	5.9	50
24	Classifying ultra-high risk smoldering myeloma. Leukemia, 2015, 29, 751-753.	7.2	37
25	RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia, 2019, 33, 2006-2021.	7.2	36
26	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Advances, 2019, 3, 2487-2490.	5.2	35
27	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. American Journal of Hematology, 2019, 94, S28-S33.	4.1	35
28	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood, 2016, 128, 5702-5702.	1.4	31
29	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 896-896.	1.4	29
30	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	1.4	28
31	Trispecific antibodies offer a third way forward for anticancer immunotherapy. Nature, 2019, 575, 450-451.	27.8	27
32	Immunotherapy with chimeric antigen receptors for multiple myeloma. Discovery Medicine, 2014, 17, 37-46.	0.5	22
33	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. Journal of Clinical Oncology, 2022, 40, 8013-8013.	1.6	20
34	Trials and Tribulations with VH Replacement. Frontiers in Immunology, 2014, 5, 10.	4.8	19
35	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. Blood, 2018, 132, 1886-1886.	1.4	19
36	Cellular and vaccine immunotherapy for multiple myeloma. Hematology American Society of Hematology Education Program, 2016, 2016, 521-527.	2.5	16

#	Article	IF	Citations
37	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 332-344.	0.4	16
38	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	7.0	15
39	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. Blood, 2019, 134, 622-622.	1.4	15
40	Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) Ã— CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, 8007-8007.	1.6	14
41	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. Blood, 2018, 132, 1973-1973.	1.4	13
42	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863.	1.4	13
43	Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. Blood, 2014, 124, 3087-3087.	1.4	13
44	Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 161-161.	1.4	13
45	Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 2119-2119.	1.4	12
46	Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking. Clinical Chemistry, 2021, 68, 230-239.	3.2	11
47	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11
48	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigenâ€"Matched Grafts. Biology of Blood and Marrow Transplantation, 2017, 23, 126-133.	2.0	10
49	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). Blood, 2018, 132, 1974-1974.	1.4	10
50	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies. Cancer Journal (Sudbury, Mass), 2016, 22, 27-33.	2.0	9
51	Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. American Journal of Hematology, 2020, 95, E28-E30.	4.1	9
52	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood, 2022, 139, 1289-1301.	1.4	9
53	Cellular immunotherapy for plasma cell myeloma. Bone Marrow Transplantation, 2013, 48, 1377-1386.	2.4	8
54	Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation. Blood, 2012, 120, 2010-2010.	1.4	7

#	Article	IF	Citations
55	Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood, 2016, 128, 4548-4548.	1.4	7
56	Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. Journal of Clinical Oncology, 2022, 40, 8007-8007.	1.6	7
57	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. British Journal of Haematology, 2021, 193, 851-855.	2.5	6
58	Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2014, 49, 1439-1441.	2.4	4
59	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. Blood, 2019, 134, 1909-1909.	1.4	4
60	Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas. Blood, 2021, 138, 1438-1438.	1.4	4
61	Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, 8035-8035.	1.6	4
62	Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e337-e338.	0.4	3
63	Multitargeted CAR T-cell therapy in multiple myeloma. Lancet Haematology,the, 2019, 6, e494-e495.	4.6	3
64	Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients. Blood, 2021, 138, 1757-1757.	1.4	3
65	Circulating Multiple Myeloma Cells (CMMCs): A Novel Method for Detection and Molecular Characterization of Peripheral Blood Plasma Cells in Multiple Myeloma Precursor States. Blood, 2014, 124, 2031-2031.	1.4	2
66	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. Blood, 2021, 138, 253-253.	1.4	2
67	Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, 8036-8036.	1.6	2
68	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, e20028-e20028.	1.6	2
69	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. Journal of Clinical Oncology, 2022, 40, 8033-8033.	1.6	2
70	Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma. Blood, 2013, 122, 3354-3354.	1.4	1
71	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	1.4	1
72	Reflections on the Role of the Professionalism Curriculum in Medical School. AMA Journal of Ethics, 2007, 9, 259-261.	0.7	0

#	ARTICLE	IF	CITATIONS
73	High-Throughput Sequencing of Antibody Genes Successfully Identifies Clonal Ig Rearrangements in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2014, 20, S74-S75.	2.0	0
74	Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. Journal of Clinical Oncology, 2021, , JCO2101754.	1.6	0
75	Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity. Blood, 2021, 138, 1707-1707.	1.4	0
76	History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies. Transplantation and Cellular Therapy, 2022, 28, S335-S336.	1.2	0